Team PowerIO at the Society for Immunotherapy of Cancer Sparkathon - this crew taught me a ton! Dr. Kristin Anderson, PhD @ImmuneKit Sangeetha Reddy Vaia Florou, MD

#SITCsparkathon reception

Answering an important question: More to come! #SITC2018 , #sparkathon, #projectSITCure, #immunotherapy

Congrats to Dr. Kristin Anderson, PhD for her talk on adoptive T cell therapy in ovarian cancer in the #sitc2018 Presidential Session - fascinating work and a great presentation!

Finally!

My first tweet honoring @breelynwilky #RedefinePossible Women’s 2019 Leadership Award @wnbachicagosky Conquer Cancer, the ASCO Foundation Congrats!!!

Can pts who develop immune-related adverse events (AEs) on PD-1 or PD-L1 inhibitor immunotherapy be re-challenged later? Cohort of 93 pts from Gustave Roussy tested, w 55% developing AEs w 2nd administration, typically less severe than 1st exposure ja.ma/2IooajP

Excited to be part of the 2018 Society for Immunotherapy of Cancer #Sparkathon on Team SITCure. When it is safe to stop checkpoint blockade? A major question in immuno-oncology (#IO) Jennifer Guerriero, PhD Sangeetha Reddy Aideen Ryan Dan Olson Vaia Florou, MD Rafeh Naqash, MD @aeoveracre David H Aggen, MD PhD Ravi Patel

In Tsiodras We Trust #inTsiodraswetrust #elladamou #COVIDー19 #Covid19Gr #KeepingItReal #coronavirus #Greece

Excited for Denver virtual #GIST Day of Learning for patients and families! Register here The Life Raft Group Vaia Florou, MD Ana Gleisner (she/her/hers) liferaftgroup.org/event/gdol-den…

.Total Health | Oncology 📖🔬 is providing free updates on the latest developments in oncology in the wake of this year’s ASCO annual meeting Join colleagues virtually from the conference occurring this weekend in Denver at the link below: bit.ly/3PFWurW

🏃🏽‍♂️🏃🏽‍♀️Society for Immunotherapy of Cancer SITC Early Career Scientist Committee 🥺plz 👍🏼 & retweet! We R #3 now 🥳Join AACR 5K Run/Walk through 😎 #SRC team 4/15 Sat 7:30am AACR in Orlando. do.nr/xjgukm Marco Ruella Jennifer Guerriero, PhD Praveen Bommareddy @gulleyj1 Nils-Petter Rudqvist Vaia Florou, MD Support! #CancerResearch 🧬🔬

New #JITC article: Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden bit.ly/3L6VQ75 Vaia Florou, MD Asaf Maoz Rafeh Naqash, MD Sonam Puri MD

Sharing 2 plots from Foundation Medicine data from the Supplementary material of this paper that I had the pleasure to work with Vaia Florou, MD Rafeh Naqash, MD Asaf Maoz: MSI-H proportion in 250,813 tumors and the distribution of TMB for MSI-H v MSS.

Countdown to 2024: #JITCTop10 - Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden bit.ly/3L6VQ75 Vaia Florou, MD Asaf Maoz Rafeh Naqash, MD Sonam Puri MD

Congratulations Thejus Jayakrishnan Alok Khorana, MD and multi-institutional collaborative team on publication in JCO Precision Oncology of this work: "Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers." ascopubs.org/doi/full/10.12…

For more details- ascopubs.org/doi/full/10.12… Thanks to experts Cleveland Clinic & across the country for their valuable contribution Suneel Kamath MD Kanika Nair Vaia Florou, MD Tiago Biachi Moh’d khushman Jash Datta, MD Emil Lou, MD, PhD, FACP Benjamin Weinberg, MD, FACP DrPatGulhati & DrSanjayGoel Rutgers Cancer Institute